As researchers continue to seek new treatments for neuropathic pain, advances in genomics are presenting new methods for modulating biological pathways that play an important role in this complex ...
FREEHOLD, N.J., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment ...
FREEHOLD, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment ...
Channel Therapeutics Corporation, a clinical-stage biotechnology company focused on non-opioid pain treatments, expressed encouragement regarding Vertex Pharmaceuticals' recent Phase 2 data for ...
Chronic pain is an extremely common condition that affects about 20% of the general population. Given the shortage of effective and non-addictive analgesics, new anti-pain drugs are eagerly awaited.
Siteone Therapeutics Inc. has provided details on the discovery of highly selective, potent, state-independent inhibitors of Nav1.7, a nonopioid target for the potential treatment of pain. While prior ...
Efforts at Abbvie Inc. to selectively target voltage-gated sodium channel subunit alpha Nav1.7 to treat pain led to the discovery of quinoline and quinolone agents and, through structure-activity ...
It's estimated that as many as one-third of Americans suffer from chronic pain, and many medications that have been developed to treat pain pose serious risks. Scientists have now created a gene ...
Researchers at NYU College of Dentistry's Pain Research Center have developed a gene therapy that treats chronic pain by indirectly regulating a specific sodium ion channel, according to a new study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results